Low-dose dopamine induces early recovery of recombinant interleukin-2-Impaired renal function

G. Palmieri, A. Morabito, R. Lauria, V. Montesarchio, E. Matano, A. Rea, C. Merola, P. Correale, L. Leo, P. Tagliaferri, A. R. Bianco, B. Memoli, C. Libetta

Research output: Contribution to journalArticlepeer-review


Recombinant interleukin-2 (rIL-2) can produce impairment of renal function with hypotension, fluid retention, elevated blood urea nitrogen, oliguria and low fractional sodium excretion; these side-effects are a common cause of reduction or interruption of rIL-2 infusion. The aim of this study was to investigate the control and treatment of renal toxicity induced by rIL-2 therapy. Here we show that dopamine, at a low dose of 2 μg/kg/min, completely prevented renal toxicity induced by rIL-2. While continuing rIL-2 therapy, 24-h continuous infusion of low-dose dopamine produced a rapid normalisation of urine output and a significant decrease in serum creatinine levels and body weight (P <0.01), with an early and complete recovery of the rIL-2-impaired renal function: mean recovery time of renal function in patients treated with dopamine was significantly lower (P <0.05) than in non-treated patients (4.8 days vs. 10 days, respectively).

Original languageEnglish
Pages (from-to)1119-1122
Number of pages4
JournalEuropean Journal of Cancer
Issue number8
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology


Dive into the research topics of 'Low-dose dopamine induces early recovery of recombinant interleukin-2-Impaired renal function'. Together they form a unique fingerprint.

Cite this